We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

103 hedge funds and large institutions have $463M invested in Praxis Precision Medicines in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

3% more funds holding

Funds holding: 100 → 103 (+3)

0.14% more ownership

Funds ownership: 6.51% → 6.65% (+0.14%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

46% less capital invested

Capital invested by funds: $863M → $463M (-$399M)

Holders
103
Holders Change
+3
Holders Change %
+3%
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
39
Reduced
26
Closed
10
Calls
$1.97M
Puts
–
Net Calls
+$1.97M
Net Calls Change
+$1.4M

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$8M
2
ACA
Avoro Capital Advisors
New York
+$5.07M
3
PHS
PFM Health Sciences
California
+$3.13M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$2.41M
5
State Street
State Street
Massachusetts
+$1.72M

Top Sellers

1
Jennison Associates
Jennison Associates
New York
-$3.82M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.61M
3
Citadel Advisors
Citadel Advisors
Florida
-$1M
4
Citigroup
Citigroup
New York
-$690K
5
Two Sigma Investments
Two Sigma Investments
New York
-$519K
Name Holding Trade Value Shares
Change 		Change in
Stake
Blackstone Inc
1
Blackstone Inc
New York
$50M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$47M +$365K +1,776 +0.6%
EAM
3
Eventide Asset Management
Massachusetts
$44.9M +$8M +38,960 +15%
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$34M -$118K -575 -0.3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$33.9M +$407K +1,980 +0.9%
VVA
6
Vida Ventures Advisors
Massachusetts
$30M – – –
BlackRock
7
BlackRock
New York
$25.8M +$453K +2,205 +1%
ACA
8
Avoro Capital Advisors
New York
$22M +$5.07M +24,666 +21%
AllianceBernstein
9
AllianceBernstein
Tennessee
$20.9M +$2.41M +11,755 +9%
Citadel Advisors
10
Citadel Advisors
Florida
$15.8M -$1M -4,881 -5%
State Street
11
State Street
Massachusetts
$14.2M +$1.72M +8,371 +10%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$13.6M -$1.61M -7,830 -8%
AG
13
Artal Group
Luxembourg
$12.3M – – –
7IH
14
72 Investment Holdings
Connecticut
$10.1M – – –
PHS
15
PFM Health Sciences
California
$8.83M +$3.13M +15,261 +36%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$8.09M +$1.37M +6,666 +14%
HMC
17
Harvard Management Company
Massachusetts
$7.95M – – –
CAM
18
Cormorant Asset Management
Massachusetts
$7.68M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$6.4M +$409K +1,993 +5%
LCM
20
Laurion Capital Management
New York
$5.57M -$98.6K -480 -1%
KCM
21
Kingdon Capital Management
New York
$4.23M – – –
Northern Trust
22
Northern Trust
Illinois
$3.24M +$45K +219 +1%
WP
23
Woodline Partners
California
$3.15M – – –
Franklin Resources
24
Franklin Resources
California
$2.81M – – –
Charles Schwab
25
Charles Schwab
California
$2.6M +$87.9K +428 +3%
1
2 3 4 5

PRAX Hedge Fund Activity: Q1 2022 in Review

103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2022, worth a combined $463M — down 46% from $863M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PRAX positions and 10 closed out — a net gain of 3 holders — while 39 added to existing stakes and 26 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $8M. The largest seller was Jennison Associates, exiting entirely with an estimated $3.82M sold.

  • 103 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2022, up from 100 in Q4 2021.
  • Funds reported $463M of Praxis Precision Medicines stock for Q1 2022, down 46% quarter-over-quarter.
  • 13 funds opened new Praxis Precision Medicines positions in Q1 2022 and 10 closed out, a net change of +3 holders.
  • The largest Praxis Precision Medicines buyer in Q1 2022 was Eventide Asset Management, an estimated $8M added.
  • The largest Praxis Precision Medicines seller in Q1 2022 was Jennison Associates, an estimated $3.82M sold.

Based on aggregated 13F filings for Q1 2022.